Eplerenone


Selective steroidal mineralocorticoid receptor antagonist with 9-alpha,11-alpha-epoxy modification conferring high receptor selectivity over androgen and progesterone receptors

A selective aldosterone antagonist derived from the spironolactone scaffold through introduction of a 9-alpha,11-alpha-epoxy group, developed across four pharmaceutical sponsors over two decades and validated in landmark heart failure and post-myocardial infarction trials as the first mineralocorticoid receptor antagonist with clinically meaningful selectivity over sex steroid hormone receptors.

Abstract

Eplerenone is a steroidal mineralocorticoid receptor (MR) antagonist and the second agent approved in this pharmacological class, reaching United States Food and Drug Administration registration in 2002 (marketed as Inspra) approximately four decades after the introduction of spironolactone, the first-generation nonselective aldosterone blocker. The compound is distinguished from spironolactone by the presence of a 9-alpha,11-alpha-epoxy bridge and a 17-alpha-carbomethoxy substituent, structural modifications that confer approximately 20- to 40-fold lower binding affinity at the mineralocorticoid receptor but approximately 500- to 800-fold greater selectivity over the androgen, progesterone, and glucocorticoid receptors. This selectivity profile eliminates the gynecomastia, breast pain, menstrual irregularity, and sexual dysfunction that limit spironolactone tolerability in chronic cardiovascular and renal indications.

The clinical evidence base for eplerenone rests on two landmark randomized controlled trials. The Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF), published in 2011 in the New England Journal of Medicine, enrolled 2,737 patients with chronic systolic heart failure (ejection fraction 35 percent or less) and New York Heart Association class II symptoms and demonstrated that eplerenone reduced the composite of cardiovascular death and heart failure hospitalization by 37 percent (hazard ratio 0.63; 95 percent confidence interval 0.54 to 0.74). These trials established eplerenone as a guideline-recommended therapy in heart failure with reduced ejection fraction and in post-myocardial infarction left ventricular dysfunction across all major international cardiovascular society guidelines.

Eplerenone is approved in the United States for hypertension and for heart failure following myocardial infarction with left ventricular dysfunction. The compound is also approved in the European Union, Japan, and multiple additional jurisdictions for heart failure with reduced ejection fraction. The pharmacokinetic profile is characterized by rapid oral absorption (time to maximum plasma concentration approximately 1.5 hours), absolute bioavailability of approximately 69 percent, elimination half-life of 4 to 6 hours, and predominant hepatic metabolism by cytochrome P450 3A4 (CYP3A4) with contributions from CYP3A5. The absence of clinically meaningful gynecomastia (0.7 percent versus 9 to 10 percent for spironolactone in controlled trials) is the principal tolerability advantage.

This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph